Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Phase 1 in Advanced Tumors
NCT03474289Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Mar 2018
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of adebrelimab in solid tumor (advanced stage) (2 arms), sponsored by Hengrui. Primary endpoints: Adverse Events at 21 days and Dose-limiting toxicities at 21 days. Status: unknown.
02
Drugs
adebrelimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03474289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474289.